Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL – Get Free Report) was the target of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 14,700 shares, an increase of 8.1% from the October 31st total of 13,600 shares. Approximately 0.5% of the company’s stock are sold short. Based on an average daily trading volume, of 17,900 shares, the days-to-cover ratio is currently 0.8 days.
Institutional Investors Weigh In On Cryo-Cell International
An institutional investor recently raised its position in Cryo-Cell International stock. Geode Capital Management LLC grew its stake in Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL – Free Report) by 68.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 39,860 shares of the company’s stock after purchasing an additional 16,203 shares during the period. Geode Capital Management LLC owned approximately 0.49% of Cryo-Cell International worth $254,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 10.44% of the stock is currently owned by hedge funds and other institutional investors.
Cryo-Cell International Trading Up 0.4 %
Shares of CCEL opened at $8.58 on Wednesday. The stock has a market capitalization of $69.11 million, a PE ratio of -8.09 and a beta of 0.49. Cryo-Cell International has a 52 week low of $4.47 and a 52 week high of $9.50.
Cryo-Cell International Announces Dividend
The business also recently declared a — dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were given a $0.25 dividend. The ex-dividend date of this dividend was Friday, November 15th. Cryo-Cell International’s dividend payout ratio (DPR) is presently -94.34%.
About Cryo-Cell International
Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.
Featured Articles
- Five stocks we like better than Cryo-Cell International
- Earnings Per Share Calculator: How to Calculate EPS
- 2 Off-Price Retail Titans: Which Stock Has More Upside in 2025?
- Health Care Stocks Explained: Why You Might Want to Invest
- Kohl’s Faces Holiday Hurdles, But Key Factors Offer Hope
- 3 Healthcare Dividend Stocks to Buy
- Dogs of the Dow: 3 Stocks Poised for a 2025 Rebound
Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with MarketBeat.com's FREE daily email newsletter.